Pres. & Chief Exec. Officer Maetzold Derek J sold $114,573 worth of shares (5,644 units at $20.30), decreasing direct ownership by 2% to 77,099 units (SEC Form 4)

$CSTL
Medical Specialities
Health Care
Get the next $CSTL alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MAETZOLD DEREK J

(Last) (First) (Middle)
C/O CASTLE BIOSCIENCES, INC.
505 S. FRIENDSWOOD DRIVE, SUITE 401

(Street)
FRIENDSWOOD TX 77546

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CASTLE BIOSCIENCES INC [ CSTL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Pres. & Chief Exec. Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/26/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/26/2025 S(1) 1,236 D $20.3(2) 77,099 D
Common Stock 03/26/2025 S(1) 2,017 D $20.3(2) 65,025 I By The Maetzold Descendants 2020 Trust(3)
Common Stock 03/26/2025 S(1) 1,731 D $20.3(2) 55,372 I By Derek Maetzold 2020 Irrevocable Trust(4)
Common Stock 03/26/2025 S(1) 165 D $20.3(2) 4,608 I By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk(5)
Common Stock 03/26/2025 S(1) 165 D $20.3(2) 4,605 I By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold(6)
Common Stock 03/26/2025 S(1) 165 D $20.3(2) 4,605 I By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold(7)
Common Stock 03/26/2025 S(1) 165 D $20.3(2) 4,605 I By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold(8)
Common Stock 122,866 I By DJM Grantor Retained Annuity Trust No. 5(9)
Common Stock 26,134 I By DJM Grantor Retained Annuity Trust No. 6(10)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on November 11, 2024.
2. This transaction was executed in multiple trades at prices ranging from $20.01 to $20.72, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.
4. Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries.
5. Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary.
6. Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
7. Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
8. Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
9. Held by DJM Grantor Retained Annuity Trust No. 5 of which the Reporting Person is the trustee and beneficiary.
10. Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold.
Remarks:
/s/ Frank Stokes, Attorney-in-fact 03/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $CSTL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CSTL

DatePrice TargetRatingAnalyst
12/14/2023$25.00Buy
Guggenheim
1/5/2023$54.00Sector Outperform
Scotiabank
1/7/2022$59.00Overweight
Stephens & Co.
11/9/2021$85.00 → $75.00Outperform
SVB Leerink
7/14/2021$80.00 → $85.00Outperform
SVB Leerink
More analyst ratings

$CSTL
Press Releases

Fastest customizable press release news feed in the world

See more
  • Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

    Two posters will share data on the significant risk stratification provided by DecisionDx-Melanoma in a real-world cohort of patients with stage IIB-IIC cutaneous melanoma (CM) to help guide adjuvant therapy, and the role of the test in prompting use of imaging surveillance in early-stage patients at high risk of metastasis to the central nervous system (CNS) FRIENDSWOOD, Texas, April 01, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, will share data via two poster presentations at the 11th World Congress of Melanoma and 21st European Association of Dermato-Oncology (EADO) Congress, being held A

    $CSTL
    Medical Specialities
    Health Care
  • Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

    New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (SCC) demonstrates that the addition of DecisionDx-SCC to Brigham & Women's Hospital (BWH) staging significantly refines metastatic risk prediction in patients classified as High-Risk and Very High-Risk by National Comprehensive Cancer Network (NCCN) guidelines to support improved, risk-aligned treatment pathway decisions Castle will also present new data showing DecisionDx®-Melanoma as a significant predictor of mortality in a real-world cohort of nearly 7,000 patients with early-stage cutaneous melanoma (CM), reinforcing its value in identifying patients who may benefit from treatment plan strategies

    $CSTL
    Medical Specialities
    Health Care
  • New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

    New study corroborates DecisionDx®-SCC's ability to independently predict metastatic risk in patients with high-risk cutaneous squamous cell carcinoma (SCC) Landmark analysis of nearly 10,000 patients through Castle's collaboration with the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program Registries showed a significant association between DecisionDx®-Melanoma testing and improved survival in melanoma patients Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, will share new data on its DecisionDx-Melanoma and DecisionDx-SCC tests for patients with skin cancers at the 2025 AAD Annual Mee

    $CSTL
    Medical Specialities
    Health Care

$CSTL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CSTL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CSTL
SEC Filings

See more

$CSTL
Leadership Updates

Live Leadership Updates

See more
  • Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

    The Company is proud to collaborate on a number of additional initiatives during the month of May Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month. The first such event is a ribbon cutting to honor the City of Friendswood's designation as a Sun Safe Leadership Model City — the first in Texas — by IMPACT Melanoma. The ribbon cutting will take place at Stevenson Park in Friendswood, Texas, on Friday, May 3, 2024, at 10:00 a.m. Central time. "Skin cancer is the most common cancer in the Unit

    $CSTL
    Medical Specialities
    Health Care
  • Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

    -Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in

    $CSTL
    $EQ
    $ICPT
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors

    SAN DIEGO, May 26, 2021  /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. Mr. Maetzold is the Founder and CEO of publicly listed Castle Biosciences (NASDAQ:CSTL). Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Castle Biosciences has gained Medicare reimbursement coverage and has had a successful

    $CSTL
    Medical Specialities
    Health Care

$CSTL
Financials

Live finance-specific insights

See more
  • Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results

    Full-year 2024 revenue of $332 million, an increase of 51% compared to 2023 and above previously reported guidance Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023 Year-end 2024 cash, cash equivalents and marketable investment securities of $293 million, a $50 million increase compared to 2023 Anticipate generating between $280-295 million in total revenue in 2025 Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended December 31, 2024. "Castle delivered an outst

    $CSTL
    Medical Specialities
    Health Care
  • Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025

    Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2024, after the close of market on Thursday, Feb. 27, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/686536610, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/default.asp

    $CSTL
    Medical Specialities
    Health Care
  • Castle Biosciences Reports Third Quarter 2024 Results

    Q3 2024 revenue increased 39% over Q3 2023 to $86 million Q3 2024 total test reports increased 41% over Q3 2023 Raising full-year 2024 revenue guidance to $320-330 million from $275-300 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September 30, 2024. "We are thrilled with our third quarter performance, which reflects the continued success of our growth initiatives and the dedication of our team," said Derek Maetzold, president and chief executive officer of Castle Biosciences.

    $CSTL
    Medical Specialities
    Health Care

$CSTL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more